A prospective, randomized, non-inferior clinical trial for antiviral therapy optimization programs for AIDS patients

INTERVENTION: Reference treatment group:Zidovudine 300mg twice daily / tenofovir 300mg once daily + lamivudine 300mg once daily + nevirapine 200mg twice daily / efavirenz 600mg once daily;Optimized treatment group:Lopinavir/ritonavir 500mg twice daily + lamivudine 300mg once daily; CONDITION: AIDS PRIMARY OUTCOME: Virological breakthrough rate (HIV RNA <400 copies/mL);CD4+T lymphocyte count.; INCLUSION CRITERIA: 1. Asians aged 18 to 60 years old; 2. with HIV antibody positive for at least 3 months and hepatitis B surface antigen negative; 3. HIV‐RNA detected in serum (PCR detection <100 000 copies/ml) ; 4. CD4+ T lymphocyte count > 200/µL; 5. All men and women of childbearing age must use effective contraception during the study period and within 3 months of the completion of treatment; 6. After 24 weeks of the national standard treatment regimen,HIV‐RNA was < 50 copies/ml.